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Abstract
Background: Alpha-enolase is a glycolytic enzyme that catalyses the formation of phosphoenolpyruvate in the cell
cytoplasm. a-Enolase and the predominantly nuclear Myc promoter-binding protein-1 (MBP-1) originate from a single gene
through the alternative use of translational starting sites. MBP-1 binds to the P2 c-myc promoter and competes with TATA-
box binding protein (TBP) to suppress gene transcription. Although several studies have shown an antiproliferative effect of
MBP-1 overexpression on several human cancer cells, to date detailed observations of a-enolase and MBP-1 relative
expression in primary tumors versus normal tissues and their correlation with clinicopathological features have not been
undertaken.
Methodology and Findings: We analyzed a-enolase and MBP-1 expression in normal breast epithelium and primary
invasive ductal breast carcinoma (IDC) from 177 patients by Western blot and immunohistochemical analyses, using highly
specific anti-a-enolase monoclonal antibodies. A significant increase in the expression of cytoplasmic a-enolase was
observed in 98% of the tumors analysed, compared to normal tissues. Nuclear MBP-1 was found in almost all the normal
tissues while its expression was retained in only 35% of the tumors. Statistically significant associations were observed
among the nuclear expression of MBP-1 and ErbB2 status, Ki-67 expression, node status and tumor grade. Furthermore
MBP-1 expression was associated with good survival of patients with IDC.
Conclusions: MBP-1 functions in repressing c-myc gene expression and the results presented indicate that the loss of
nuclear MBP-1 expression in a large number of IDC may be a critical step in the development and progression of breast
cancer and a predictor of adverse outcome. Nuclear MBP-1 appears to be a novel and valuable histochemical marker with
potential prognostic value in breast cancer.
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Introduction
Breast cancer development is the result of an accumulation of
molecular abnormalities that activate oncogenes and inactivate
tumor suppressor genes. Understanding the biology of the disease
is critical for developing novel strategies for early detection,
prevention, classification and treatment.
Enolase was originally characterized as an enzyme involved in
glucose metabolism. Three enolase isoforms have been found in
mammalian cells, they are named a-( E N O 1 ) ,b- (ENO3), and c-
(ENO2) enolase. The expression of these isoforms is develop-
mentally regulated in a tissue-specific manner: the ENO1 gene
product is widely distributed in a variety of tissues, whereas the
ENO2 and ENO3 products are primarily found in neuron/
neuroendocrine and muscle tissues, respectively. Enolase forms
homodimers or heterodimers to convert 2-phosphoglycerate into
phosphoenolpyruvate in the glycolytic pathway. More recent
evidence, however, indicates that a-enolase is a multifunctional
protein [1]. In addition to its glycolytic function, which is
primarily exerted in the cytoplasm, a-enolase has been found on
the cell surface, where it functions as a plasminogen receptor,
implying that membrane-bound enolase may play a role in
inflammation and tissue invasion [2]. In hypoxic situations, a-
enolase also acts as a stress protein and it has been speculated that
its up-regulation may provide protection to cells by increasing
anaerobic metabolism [3].
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several cancer cell models, whereas the clinical correlation of
ENO1 expression to tumor status has not yet been clearly defined.
Up-regulation of ENO1 has been reported in several highly
tumorigenic or metastatic cell lines derived from alveolar type II
pneumocytes [4], small cell lung cancer [5], head and neck cancers
[6]. Similarly, studies examining enzymatic activities in breast
cancer indicated a role for a-enolase in tumor progression [7].
Two recent studies, one reporting the overexpression of a-enolase
in 18 out of 24 different types of cancer, including breast cancer
[8], the other demonstrating the association of phosphorylated
isoforms with pancreatic ductal adenocarcinoma [9], further
support a correlation between ENO1 expression and its general
pathophysiological role in cancer formation. By using an
alternative translation start codon, ENO1 transcripts, which
encode the full length polypeptide of about 48 kDa, can also be
translated into a shorter protein (37 kDa), called Myc promoter-
binding protein-1 (MBP-1) [10,11], which acts as a negative
regulator of c-myc gene expression by interacting with the major
promoter [12,13]. So far, several MBP-1-associated proteins have
been identified, including histone deacetylase HDAC1 [14],
MIP2A/sedlin [15,16], MEK5a [17], NS1-BP [18], and the
Notch1 receptor intracellular domain [19]. The target genes of
MBP-1 transcriptional activity remain unclear except for c-myc
and, as recently reported, COX2 [20]. It has been reported that
MBP-1 may regulate target genes at least in part through the p53–
p21 pathway [21]. Mounting evidence indicates that both a-
enolase and MBP-1 might be involved in tumorigenesis of breast
carcinoma [22], non-small cell lung cancer [23,24], hepatitis C
virus–related hepatocellular carcinoma [25], prostate tumor
[17,26], squamous cell carcinoma [27] and neuroblastoma [28].
It has also been shown that MBP-1 expression reduces the invasive
ability of breast cancer cells both in vitro and in a mouse model
[22,29], and a-enolase may participate in the control of epithelial
to mesenchymal transitions [30]. While the role of the exogenous
expression of MBP-1 in transcription and cell growth regulation
appears to be established, the in vivo function of this protein is
poorly understood. Detailed observations of a-enolase and MBP-1
expression and localization in human breast epithelium and breast
carcinomas have not been undertaken thus far.
In the present study, by using highly specific monoclonal
antibodies to a-enolase, we confirm that ENO1 is significantly
overexpressed in primary breast tumor specimens. Furthermore,
we report for the first time the characterization of MBP-1
expression in primary breast cancers of different histological
grades from patients with various clinicopathological features.
Immunohistochemical and Western blot analyses indicate that
nuclear expression of MBP-1 inversely correlates with the
prognosis of disease recurrence for patients with IDC. Using
multivariate analysis, the effectiveness of nuclear MBP-1 expres-
sion as a prognostic factor was assessed. Our results strongly
suggest that MBP-1 could be an independent biomarker for the
prediction of breast cancer progression and/or outcome.
Materials and Methods
Patients information and tissue specimens
Women with histological verified IDC, treated at the Depart-
ments of Surgery and Oncology, La Maddalena Hospital,
Palermo, from 2001 to 2008 were included in the study. Patients
with in situ carcinoma, distant metastases at the time of the
diagnosis, synchronous or metachronous bilateral breast cancer,
malignancy other than breast cancer in history, and women who
did not undergo breast surgery were excluded. The 177 patients,
of whom sufficient clinical data and histologic specimens could be
retrieved, were chosen for the analysis. Tumor tissues were
submitted to routine histopathologic examination. Among the 177
patients, 79 were followed up for the first 5 years after the
diagnosis at 6-month intervals. The median age at the time of the
diagnosis was 59 years (range 31–83 years). The median duration
of the follow-up of the patients still alive was 5.1 years (range 2.5–
6.1 years) and of all the patients 4.0 years (range 0.3–6.1 years).
Representative clinical and histological data of the IDC patients
are summarized in Table 1. All experiments using human tissues
were performed with the written patients’ informed consent and
with the approval of Institutional Review Boards from La
Maddalena Hospital.
Table 1. Correlation between MBP-1 expression and
clinicopathological characteristics of breast cancer patients.
Variable Total (%)
MBP-1 nuclear
immunoreactivity P
Positive (%) Negative (%)
Age (yr)
#50 51 (29) 15 (23) 36 (32)
.50 126 (71) 51 (77) 75 (68) NS
Tumor size
#2 cm 68 (38) 28 (42) 40 (36)
.2 cm 109 (62) 38 (58) 71 (64) NS
Node status
negative 85 (48) 44 (67) 41 (37)
positive 92 (52) 22 (23) 70 (63) 0.0002
Tumor grade
1–2 80 (45) 43 (65) 37 (33)
3–4 97 (55) 23 (35) 74 (67) ,0.0001
ErbB2
negative 122 (69) 58 (88) 64 (58)
positive 55 (31) 8 (12) 47 (52) ,0.0001
ER
negative 39 (26) 15 (59) 24 (25)
positive 112 (74) 41 (61) 71 (75) NS
PG
negative 57 (38) 16 (29) 41 (43)
positive 94 (62) 40 (71) 54 (57) NS
Ki67
negative 33 (19) 19 (29) 14 (13)
positive 144 (81) 47 (71) 97 (87) 0.0096
Recurrences
recurrent 32 (40) 4 (17) 28 (51)
non recurrent 47 (60) 20 (83) 27 (49) 0.0057
Death for disease
Yes 19 (24) 3 (13) 16 (29)
No 60 (76) 21 (87) 39 (71) NS
NOTE: Statistical analyses were done by the Fisher’s exact test. A P value of
,0.05 was considered significant.
Abbreviations: ER, estrogen receptor; PG, progesterone receptor;
NS, nonsignificant.
doi:10.1371/journal.pone.0012961.t001
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Anti-a-enolase monoclonal antibodies (mAbs) were generated
by immunizing mice with a GST-enolase chimeric peptide as
described previously [31]. Two mAbs specific to the N-terminus
(ENO-276/3) and the C-terminus (ENO-19/8) of human a-
enolase were affinity-purified on ProtA-Sepharose 4B (Amersham
Biosciences, Sweden). The affinity-purified anti-a enolase mAbs
were used for immunohistochemical and Western blot analysis.
Anti-c-Myc antibody (sc-40) was purchased from Santa Cruz
(Santa Cruz Biotechnology, CA), rabbit anti-Flag antibody (M2)
was from Sigma (Sigma Chemical Company, St Louis, MO).
For Western blot analysis frozen tissue (about 100 mg) was
homogenized in 500 ml of ice-cold RIPA buffer (50 mM Tris
pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 1% sodium
deoxycholate, 1 mM EDTA, 0.5 mM DTT) with freshly added
protease and phosphatase inhibitors (Sigma Chemical Company,
St Louis, MO). After 30 min incubation on ice, samples were spun
at 12.000 rpm for 20 min at 4uC and supernatants were collected.
Human embryonic kidney 293T cells were transiently transfected
with Flag-Eno and Flag–MBP-1 expressing constructs as previ-
ously reported [18]. Total cell lysates were prepared by directly
harvesting cells in RTB buffer (8 M Urea, 2 M Thiourea, 4%
CHAPS, 100 mM DTT) supplemented with protease and
phosphatase inhibitors. Transfection efficiency (about 80%) was
assessed in parallel cultures by the use of a vector expressing b-
galactosidase and protein extracts were screened for the presence
of recombinant enolase breakdown products by preliminary
analysis with anti-Flag antibodies. Only lysates with no detectable
breakdown products were used for further analysis.
Protein concentrations from tissue and cell lysates were
determined by the Bradford protein assay (BioRad, Hercules,
CA). Aliquots corresponding to 30 mg of samples were separated
on 4-12% polyacrylamide gradient gels (Invitrogen, Carlsbad,
CA), and electrotransferred to PVDF membrane (Amersham
Biosciences, Sweden), according to manufacturer’s instructions.
Membranes were probed with primary antibodies and horseradish
peroxidase-conjugated secondary antibodies (Amersham Biosci-
ence, Sweden). To ensure equal loading of protein among samples,
membranes were additionally probed with b-actin antibody
(Sigma Chemical Company, St Louis, MO). Detection was
performed with chemiluminescent substrates (Pierce Biotechnolo-
gy, Rockford, IL) and densitometric analysis was used to quantify
signals.
RNA extraction, reverse transcription, and real-time PCR
Total RNA from breast tumor samples was extracted using
Trizol reagent (Invitrogen, Carlsbad, CA) according to the
manufacturer’s instructions. RNA was reverse-transcribed into
cDNA by using Superscript II reverse transcriptase (Invitrogen,
Carlsbad, CA) as described previously [32]. Amplification
reactions were performed in a 25 ml reaction volume containing
about 20 ng total RNA equivalents, 20 pmoles of c-myc specific
primers (SABioscience, Frederick, MD) and the Power SYBER
Green PCR ready-mix using a 7300 thermal cycler (Applied
Biosystems, Foster City, CA). PCR conditions were: denaturation
at 95 Cu for 3 minutes, followed by 35 cycles 95 Cu for 20 seconds,
60 Cu for 15 seconds, and 72 Cu for 15 seconds, and a final
extension at 72uC for 7 minutes. Reaction specificity was
controlled by post-amplification melting curve analyses and
agarose gel electrophoresis of the amplified products. To correct
for the experimental variations between samples, Ct value of
TATA-binding protein (TBP) mRNA, amplified with specific
primers (SABioscience, Frederick, MD), was determined in each
PCR reaction. All data shown were generated from three
independent experiments and are expressed as mean 6 SD.
Immunohistochemistry
Immunohistochemistry was performed on BR804 Breast
Tumor Tissue Array (US Biomax Inc., Rockville, MD, USA),
and on tissue sections from archived formalin-fixed, paraffin-
embedded tissue blocks from patients. For all samples, a-enolase,
estrogen receptor (ER), progesterone receptor (PR), human
epidermal growth factor receptor 2 (ErbB2) and Ki67 status were
assessed by immunohistochemistry. From each individual paraffin-
embedded block serial sections of 3 mm were cut, deparaffinized in
xylene and hydrated in a graded series of alcohol. After antigen
retrieval in citrate buffer, staining was performed using the
BenchMark automated staining system (Ventana Medical System,
Tucson, AZ, USA) with primary antibodies against ER-a (SP1,
dilution 1:500), PR (1E2, dilution 1:500), Ki67 (30-9, dilution
1:500), c-ErbB2 (4B5, dilution 1:500), a-enolase affinity purified
monoclonal antibodies (mAbs) (ENO-19/8 and ENO-276/3,
1.0 mg/ml). Rabbit anti-human polyclonal antibodies were used
as a negative control (dilution 1:500). In this study, ER, PR and
Ki67 staining were scored as positive when more than 10% of
tumor cells showed staining. Tumors were graded as ErbB2-
positive with a score of 3+ and negative with a score of 0 or 1+,
according to common pathological guidelines. Tumors ErbB2-
positive 2+ were evaluated by in situ hybridization (FISH) with a
dual-color probe (PathVysion ErbB2/CEP17; Vysis, Downers
Grove, IL, USA), according to manufacturer’s instructions, and
scored positive when ErbB2 gene amplification was found.
An immunohistochemical grading scale for a-enolase expression
into the cytoplasm and nucleus, ranging from none (0) to weak (1),
or moderate (2) to strong (3), was empirically determined. In
addition, for nuclear staining, the percentage of cells labeling was
graded as negative for #20%, or positive for .20%. To confirm
the specificity of the a-enolase-staining serial sections of a subset of
the specimens (n=12) were stained using antibodies preadsorbed
for 1 hour at room temperature with the antigenic peptides for
mAbs ENO-276/3 or the recombinant a-enolase-GST polypep-
tide [31] for mAbs ENO-19/8. The staining intensity of normal
breast glands for a given patient was assessed from sections of
margin tissue blocks or from morphologically-identified normal
glands within the same slide containing malignant tumors. Normal
mammary tissues identified either adjacent to the tumor cells,
and/or on corresponding margin tissue sections, were analyzed in
158 cases. Slides were visualized with light microscopy and
qualitatively scored while blinded to clinicopathological variables.
Statistical Analysis
A database containing a-enolase and MBP-1 status and relevant
covariables was assembled and analyzed using GraphPad Prism
version 4.02 for Windows (GraphPad Software, Inc. La Jolla, CA,
USA). The association between MBP-1 expression and molecular
and clinicopathological variables was assessed using contingency
table methods and tested for significance using the Fisher’s exact
test. Correlations were determined using the non-parametric
Spearman’s test. Life tables were computed according to the
Kaplan-Meier method. Distant disease-free survival was calculated
from the date of the diagnosis to the occurrence of metastases
outside the regional area or to death from breast cancer. Patients
who died from intercurrent causes were censored at the date of
death. Survival curves were compared with the Cox-Mantel log
rank test. The significance of various variables for survival was
analyzed by the Cox proportional hazards model in the
multivariate analysis. All tests of statistical significance were two-
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Results
a-Enolase but not MBP-1 is overexpressed in the majority
of human breast tumors
To evaluate the levels of a-enolase (48 kDa) and MBP-1 variant
(37 kDa) expression in a set of tumor samples with paired normal
breast tissues from 24 patients with IDC, Western blot analysis was
performed using a previously described monoclonal antibody
(ENO-19/8) which recognises both proteins [18]. Expression was
correlated to Myc protein levels in the same samples. A
representative Western blot analysis is shown in Figure 1A, while
the averaged tumor/normal tissue ratios of a-enolase, MBP-1 and
myc protein levels for the same samples, after normalization for b-
actin expression, are graphically represented in Figure 1B.
All normal breast tissues showed moderate expression of a-
enolase, whereas stronger expression was observed in the paired
tumor samples; overall MBP-1 displayed an opposite pattern of
expression and, as expected, higher levels of Myc protein were
detected in tumors compared to normal tissues.
Statistical analysis of Western blot data confirmed the presence
of significantly higher levels of a-enolase protein in breast cancer
samples than in normal tissues (p,0.001, Figure 1C).
MBP-1 has been reported to act as a c-myc gene transcriptional
repressor; therefore we investigated c-myc mRNA level in the
same samples by quantitative reverse transcription polymerase
reaction (qRT-PCR). The relative mRNA levels of c-myc showed
a significant association with MBP-1 protein status (p,0.001) and
Figure 1. Relative expression of a-enolase, MBP-1 and Myc in primary breast tumors and adjacent normal tissue. A. Representative
Western blot analysis of a-enolase (a-eno), MBP-1, Myc and b-actin proteins in total lysates (30 mg) from breast tumors (T) and normal-matched
tissues (N) was performed as described in materials and methods. B. Graphic representation of the averaged tumor/normal (T/N) ratios of a-enolase
(white bars), MBP-1 (striped bars) and Myc (black bars) protein expression quantified by the densitometric analysis of Western blot results. Expression
levels were normalized to b-actin. Columns are the mean of three parallel experiments; bar, 6SD. C. a-Enolase protein levels in normal and breast
cancer tissues. The Box plot represents the a-enolase/b-actin ratio determined in 24 breast tumors and 21 normal-matched tissues. Significantly
higher levels of a-enolase were present in breast cancers than normal tissues (t-test value, p,0.001). D. Myc mRNA expression levels in normal and
breast cancer tissues. Transcripts were analyzed by real-time PCR and normalized with respect to TBP mRNA. Box plot of c-myc mRNA levels in MBP-1-
positive (+
ve) and negative (2
ve) breast tumors. Myc mRNA levels are significantly associated with MBP-1 status (t-test value p,0.001). In C and D bars
above and below the boxes represent the maximum and minimum expression. Each box delineates the first to third quartiles of expression, and the
central bar represents the median.
doi:10.1371/journal.pone.0012961.g001
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that retained MBP-1 than in those that did not (Figure 1D).
All together these results, in line with those previously reported,
further suggest that repression of c-myc is exerted by the
alternatively translated MBP-1 protein rather than a-enolase,
although both proteins can bind to the c-myc promoter [10,11].
Enolase nuclear immunoreactivity and MBP-1 expression
To further investigate the significance of a-enolase and MBP-1
expression in breast cancer, we firstly analyzed protein expression
in a series of patients with IDC using a commercially available
tumor tissue array (TMA) and the ENO-19/8 monoclonal
antibody.
The 35 tumor samples and adjacent normal breast tissues,
present in the TMA, exhibited various intensities of nuclear and/
or cytoplasmic staining; strong cytoplasmic staining confirmed that
higher levels of a-enolase are present in cancer lesions than in
surrounding tumor-adjacent normal tissues, as shown by Western
blot analysis (Figure 1A–C).
Interestingly, nuclear staining was detected in 12 out of 35
(34%) tumor samples, whereas nuclear staining of moderate to
strong intensity was detected in almost all (97%) the adjacent
normal mammary tissues.
Studies conducted so far on tumor samples and normal tissues
rely on the use of commercially and non-commercially available
antibodies recognizing both a-enolase and MBP-1, this has
hampered the possibility to clearly evaluate the relative expression
of the two proteins by immunohistochemistry. This observation
prompted us to further characterize a number of monoclonal
antibodies we have previously generated against a-enolase [31].
Epitope mapping was performed using full length and truncated
recombinant a-enolase expressed in bacteria and synthetic
peptides, results were confirmed by the ectopic expression of the
wild type antigen and deletion mutants in human cells (data not
shown). This wide screening allowed to select a monoclonal
antibody, ENO-276/3, which recognizes an epitope within the
NH2-portion of a-enolase (amino acids 50–95) and to map
ENO19/8 binding site to an a-enolase region between amino
acids residues 275 and 344 (Figure 2A).
Both ENO-19/8 and ENO-276/3 antibodies were finally
tested on human embryonic kidney 293T cells transiently
transfected with vectors expressing Flag-tagged a-enolase or
MBP-1 (17, Figure 2A). Western blot analysis of protein lysates
from 293T, which express very low levels of endogenous MBP-1,
confirmed that ENO-276/3 antibody detects only the 48 kDa
peptide, whereas ENO-19/8 antibody detects both the 37 kDa
MBP-1 variant of a-enolase that lacks the first 96 aminoacids
[10,11] and the catalytic 48 kDa form, (Figure 2A). In optimal
experimental conditions (80% transfection efficiency) a small
amount of MBP-1 protein, arising from the alternative transla-
tion of the exogenous transcript for a-enolase, was detected
(Figure 2A, right panel), as supported by the apparent molecular
weight and the lack of reaction of both anti-Flag and ENO-276/3
antibodies, which indicates the absence of the NH2-terminal
portion.
Reprobing the normal and breast tumor lysates shown in
Figure 1A with ENO-276/3 antibody gave similar results to those
obtained in transfected cells: a-enolase but not MBP-1 was
detected in all the samples (data not shown).
Once defined the reactivity of the two monoclonal antibodies,
immunohistochemistry was performed on serial sections of normal
breast tissue and IDC from the commercial TMA, nuclear and
cytoplasmic staining were detected using ENO-19/8 antibody
(Figure 2B, a and c) and an almost exclusive cytoplasmic staining
using ENO-276/3 antibody (Figure 2B, b and d). Furthermore, an
antigenic peptide or the recombinant a-enolase-GST polypeptide
completely blocked the immunohistochemical staining by ENO-
276/3 and ENO-19/8 antibody, respectively (Figure 2B, e and f),
confirming the specificity of the reactions.
Finally, to correlate Western blot results with immunohisto-
chemical data and to exclude the possibility of different antibody
reactivity in different experimental approaches, lysates and tumor
sections from the same samples were analyzed with both
antibodies. As expected presence of the 37 kDa MBP-1 variant
consistently correlated with nuclear staining in histochemical
analysis (Figure 2C).
Altogether these results indicate that the anti-a-enolase
antibodies used in our study specifically recognize MBP-1 and/
or a-enolase, and strongly support that the observed nuclear
staining is indicative of antibody reactivity to MBP-1.
Cytoplasmic a-enolase and nuclear MBP-1 expression:
correlation to clinicopathological features of breast
carcinomas
To further investigate ENO1 gene products expression and
localization in a larger number of samples, immunohistochemical
analyses were performed using anti-a-enolase monoclonal ENO-
19/8 as primary antibody. A series of 177 IDCs including for
almost all the cases the adjacent normal breast tissue and the
corresponding invasive cancer from the same patient were
examined. Staining was observed in both the cytoplasm and
nuclei of normal epithelium in 165 samples, which is consistent
with the normal tissue microarray data. However, 66 out of 177
(37%) tumor specimens showed the loss or down-regulation of
Figure 2. Monoclonal antibodies ENO-276/3 and ENO-19/8 specifically recognize a-enolase or both a-enolase and MBP-1. A. Top,
schematic representation of Flag-tagged constructs used, black boxes indicate the position of the Flag epitope, and numbers indicate the first and
last amino acid in each construct. Protein regions containing the epitopes recognized by ENO-276/3 and ENO-19/8 mAbs are indicated by striped and
dotted bars respectively, numbers refer to corresponding amino acids in the a-enolase sequence (Swiss-Prot: P06733). Bottom, Western blot analysis
of 293T cells transiently transfected with vectors expressing Flag-tagged a-enolase (Flag-Eno), or MBP-1 (Flag-MBP-1) proteins, compared to mock
transfected cells (mock). Cell lysates (20 mg) were firstly probed with polyclonal anti-Flag antibodies and, after stripping, the same filter was reacted
with anti-a-enolase ENO-276/3, and finally with ENO-19/8, as indicated. Molecular weight (kDa) are indicated on the right. Relative positions of
endogenous (end.) and ectopically expressed (exo.) a-enolase and MBP-1 from transfected pFlag-ENO are indicated on the left. B. Representative
immunohistochemical staining on serial sections of a normal mammary tissue (a and b) and an IDC tumors sample (c and d) from the commercial
TMA. The anti-a-enolase mAbs ENO-19/8 specifically decorated both nuclei and cytoplasm, while ENO-276/3 gave an almost exclusive cytoplasmic
staining. As a control, breast cancer sections (e and f) were immunoassayed with mAbs which had been previously coincubated and thereby blocked
with antigenic peptides, as described in materials and methods. Magnification: 5006(a–d), and 2006(e and f). C. Representative Western blot and
immunohistochemical analyses of normal and tumor tissues from IDC samples. Left, Western blot detection of a-enolase (a-eno) and MBP-1 proteins
in total lysates (30 mg) from a breast tumor sample (T) and normal-matched tissue (N) using mAbs ENO-276/3 and ENO-19/8. Anti-b-actin antibodies
were used as a control for loading. Right, immunohistochemical staining with mAbs ENO-276/3 and ENO-19/8 of serial sections of the tumor (b and d)
and the corresponding normal breast tissue (a and c) from the same sample analyzed by Western blot. Magnification: 4006.
doi:10.1371/journal.pone.0012961.g002
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A. Representative immunohistochemical staining of 3 out of the 177 IDC samples analyzed with mAbs ENO-19/8. Tumor sections (T) were compared
with the corresponding normal breast tissue (N). All normal breast tissues showed nuclear MBP-1 expression and low expression of cytoplasmic a-
enolase (sample 1–3). In sample 1 and 2, cytoplasmic staining of the invasive breast carcinoma (T) was stronger than in the matched normal breast
tissues. In tumor samples 2 and 3, the loss of MBP-1 nuclear expression occurred. Sections of sample 4 were immunoassayed with antibodies blocked
with a recombinant a-enolase polypeptide (see materials and methods). Magnification: 2506. B. MBP-1 nuclear staining correlated with ErbB2 and
Ki67 expression. Immunohistochemical staining for a-enolase, ErbB2 and Ki67 in MBP-1-positive (S1) and MBP-1-negative (S2) tumors. Magnification:
5006.
doi:10.1371/journal.pone.0012961.g003
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In Figure 3A are shown three representative IDC samples
immunostained for a-enolase, one with strong nuclear staining
(T, sample 1), and two with close to negative nuclear staining (T,
sample 2 and 3).
As for the TMA, a significant number of normal and tumor
samples showing nuclear staining were randomly selected and
serial sections probed with the ENO-276/3 antibodies specific for
full-length a-enolase (see Figure 2C for representative immuno-
histochemistry). As expected no nuclear staining was observed in
all the samples examined, confirming that the nuclear immuno-
reactivity detected by ENO-19/8 is likely due to MBP-1, although
it cannot be excluded its presence also in the cytoplasm.
Interestingly, additional immunohistochemical screening indi-
cated that nuclear staining inversely correlates with ErbB2 and
Ki67 expression in the large majority of the examined samples (see
Figure 3B).
All the 177 tissue samples included in this study scored
positively for the expression of cytoplasmic a-enolase and
according to signal intensity they were graded as weak, moderate
and strong: 31 (18%) had weak staining, 69 (39%) moderate and
77 (43%) very strong. With respect to the number of enolase
labelled cells, at least 50% cytoplasmic labeling was observed in
all cases. In addition, a-enolase expression was predominantly
detected in the cytosol of tumor cells, whereas a weak staining was
observed in stromal and myoepithelial cells. All normal breast
tissues showed moderate expression of cells labelled a-enolase,
whereas stronger expression was observed in the paired tumor
samples, however, no significant correlation between expression
of the protein and clinicopathological characteristics of tumors or
patients outcome was observed.
To grade tumors relatively to MBP-1, a cut-off value for nuclear
MBP-1 expression was chosen on the basis of a measurement of
heterogeneity using the log-rank test statistical analysis with respect
to disease-free survival. An optimal cut-off value was identified as
20% of stained nuclei, and it was used to define tumors as MBP-1-
negative (#20%, absent/low expression) or MBP-1-positive
(.20%, medium/high expression). Statistical analyses were done
to examine the correlation between nuclear MBP-1 expression, as
detected by immunohistochemical staining, and the clinicopath-
ological characteristics of breast cancers. As shown in Table 1, in
patients with IDC no correlation was found between the
expression levels of nuclear MBP-1 and patient age, tumor size,
death by disease or estrogen and progesterone receptors
expression levels. In contrast, MBP-1 expression strongly corre-
lated with the node status (P=0.0002), tumor grade (P,0.0001)
and expression levels of ErbB2 (P=0.0001) and Ki67 (P=0.0096)
proteins. These data were further confirmed by employing the
Spearman correlation analysis to test the correlation between
MBP-1 expression and the clinicopathological features. As shown
in Table 2, the Spearman correlations of nuclear MBP-1
expression levels to node status, tumor grade, recurrence of
metastasis, and the expression of ErbB2 and Ki67 were: 20.233
(P,0.0001), 20.289 (P.0.0001). 20.226 (P=0.022), 20.189
(P=0.005), and 20.220 (P=0.001), respectively. Taken as a
whole, the expression of MBP-1 was negatively correlated with
clinical staging.
Nuclear MBP-1 Expression is associated with Recurrence-
Free Survival in Breast Cancer
To test nuclear MBP-1 expression as a potential predictor of
survival it was correlated to patient’s status in a statistically
significant number of IDC. The loss of nuclear MBP-1 expression
in breast cancer tissues significantly predicted local recurrence. In
a five year follow-up, MBP-1-positive expression significantly
correlated with a 92% local recurrence-free survival. In contrast,
for IDC samples that showed the loss of MBP-1 expression,
recurrence-free survival fell to 54% at five year after surgery
(p=0.0036) (Figure 4).
A multivariate analysis was performed, according to Cox
regression model, for disease-free survival, including as covariates
MBP-1, ErbB2 expression and lymph node status. These last two
factors were chosen based on the results of the univariate analysis
(data not shown) and because they are known to influence survival
of breast cancer patients. Nuclear MBP-1 expression was found to
be an independent favourable prognostic indicator for disease-free
survival (Table 3). Thus, nuclear MBP-1-negative staining,
revealed by immunohistochemistry, could be an important marker
to select breast cancer patients for increased vigilance in follow-up
and adjuvant therapy.
Discussion
The present study provides novel and important findings on the
expression and subcellular distribution of a-enolase and MBP-1
proteins in normal breast tissue and tumors.
Table 2. Spearman correlation analysis between MBP-1 and
clinicopathological features.
Variables MBP-1 nuclear expression
Sperman correlation (p)
Node status 20.233 (,0.0001)
Tumor grade 20.289 (,0.0001)
ErbB2 status 20.189 (0.005)
Ki67 status 20.220 (0.001)
Recurrences 20.226 (0.022)
doi:10.1371/journal.pone.0012961.t002
Figure 4. Survival analysis of IDC patients according to MBP-1
expression. Kaplan-Meier curves for disease-free survival (DFS) in 77
IDC patients relative to nuclear MBP-1 positive (+
ve) or negative (2
ve)
expression. The absence or low expression (MBP-1
2ve) of nuclear MBP-1
was significantly associated with recurrence (P=0.0036 by log-rank
test).
doi:10.1371/journal.pone.0012961.g004
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repressor MBP-1 arise from the ENO1 gene and differ for the
first 96 amino acids residues, not present in the MBP-1 variant.
To date several studies have reported a-enolase immunoreac-
tivity in cytoplasm, nucleus and cell membrane. The predom-
inantly cytoplasmic localization of the glycolytic enzyme a-enolase
has been widely demonstrated in cell lines by subcellular
fractionation, while we and others have shown nuclear accumu-
lation of exogenous MBP-1 compared to the full length protein
[10,16,18,27]. Previous histochemical studies conducted on tumor
samples and normal tissues have reported three expression
patterns of ENO1 gene products: cytoplasm, nuclei and both
nuclei and cytoplasm [23,27]. To date, only one study has
reported the identification of a-enolase as a nuclear protein in
human adrenal cortex [33].
Our data, based on the use of highly specific monoclonal
antibodies, show that: i) nuclear staining in normal and tumor
breast tissue is mainly due to MBP-1 expression; ii) nuclear MBP-1
is a common feature of normal breast tissue; iii) MBP-1 expression
is associated with good survival of patients with IDC. Thus, MBP-
1 is the first transcriptional repressor whose expression has the
potential to predict a good outcome in breast cancer.
Our finding of a frequently decreased expression of MBP-1
protein in IDCs supports a role for MBP-1 as a tumor suppressor
and raises questions concerning the mechanism responsible for its
loss in these tumors. It is interesting to note that the ENO1 gene,
encoding a-enolase and MBP-1, is located in the distal short arm of
chromosome 1 [34] within one of the most frequent regions of loss
of heterozygosity (LOH) observed in node negative breast cancers
with poor prognosis [35], as well as brain tumors and hematopoietic
neoplasms, suggesting that MBP-1 could be a candidate tumor
suppressor in that region. Studies on neuroblastoma seem to rule
out that mutations inactivating the ENO1 gene are involved in
controlling MBP-1 expression [28]. Our preliminary studies on
LOH of the chromosome region surrounding the ENO1 locus
(1p36.3) in the IDC samples did not revealed any correlation
between 1p36.3 LOH and MBP-1 loss of expression. In addition,
we did not find a correlation between nuclear MBP-1 expression
and cytoplasmic a-enolase levels in IDC. These data suggest that
MBP-1 expression isregulatedindependentlyfrom theexpression of
the catalytic cytoplasmic isoform.
Recently, it has been reported that altered glucose concentra-
tion [36] and hypoxia [37] result in the differential translation of
a-enolase/MBP-1-encoding mRNA in the MCF-7 breast cancer
cell line, strongly suggesting that posttranscriptional mechanisms
might play a role in the regulation of MBP-1 expression in breast
cancer cells. Studies are ongoing to identify the mechanisms
involved in MBP-1 down-regulation in these tumors.
Ectopic expression of MBP-1 has been reported to suppress
tumorigenicity of breast cancer [22], and prostatic cancer [38] cell
lines in nude mice, suggesting the significance of MBP-1
expression as an indicator of favorable prognosis and a protective
role of MBP-1 against cancer progression. Recently, it has been
shown that MBP-1 overexpression results in the modulation of
MMP-2 expression, the inhibition of in vitro angiogenesis and the
regression of primary and metastatic breast tumor growth in an
immunocompetent mouse model, [29].
In agreement with these findings, in our study on human
primary tumors, nuclear MBP-1 expression was associated with
good outcome, further supporting that the disregulation of MBP-1
expression may play an important role in promoting cancerogen-
esis and the progression of breast cancer.
In conclusion, we present evidence that nuclear MBP-1, which
inversely correlated with ErbB2 and Ki67 protein expression,
could be used as an independent prognostic variable of clinical
outcome and may represent a potential target for therapy in
primary IDC patients. This suggests that patients with IDC, who
show the loss of nuclear MBP-1, are at higher risk of recurrence
and death from disease and may eventually benefit from more
aggressive adjuvant therapy. However, the reliability of MBP-1 as
a potential marker in the routine clinical assessment and
management of patients with IDC deserves further evaluation in
long-term follow-up studies on a larger number of cases.
In addition, functional studies are required to elucidate the role
of MBP-1 and its downstream and upstream regulatory pathways
in the pathogenesis of IDC.
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